

Precision Medicine for L/GCMN and Melanoma 2

NCT06605443

Status	RECRUITING
Sponsor	Fundacion Clinic per a la Recerca Biomédica
Enrollment	100 participants

Plain Language Summary

This study is investigating whether specific chemicals released through a person's breath or skin — called volatile organic compounds (VOCs) — can serve as a non-invasive marker to help diagnose and monitor melanoma, a type of skin cancer. It also studies large birthmarks (congenital nevi) that can develop into melanoma.

****You may be eligible if...****

- You are 18 years or older
- You have a confirmed melanoma diagnosis (stage II, III, or IV)
- You are willing to sign an informed consent form

****You may NOT be eligible if...****

- You refuse to sign the informed consent form
- You have other cancers or chronic conditions such as diabetes or asthma (which could interfere with the VOC analysis)

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (2)

- Be over 18 years old
- Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)

Exclusion (2)

- Not signing the informed consent form
- Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles

Locations (3 total)

Hospital Clínic de Barcelona (Dermatology service), Barcelona, Spain
Hospital Clínic Barcelona, Barcelona, Spain
Hospital Clínic Barcelona, Barcelona, Spain

<https://clinicaltrials.gov/study/NCT06605443>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).